Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Huge Interest In EMA's Public Hearing On Side-Effects Of Quinolones, Fluoroquinolones

Executive Summary

The European Medicines Agency has chosen 23 speakers from 55 requests made by people interested in sharing their experiences with the use of these widely-prescribed antibiotics.

You may also be interested in...



EMA Acts On Patient Concerns Over Fluoroquinolone Antibiotics

Three months after hearing testimonies of patients who suffered severe side-effects from the use of quinolones and fluoroquinolones, the European Medicines Agency has recommended that some of these medicines should be removed from the market and the labeling of others should be changed to restrict their use.

 

EU Patients Decry Medical ‘Ignorance’ About Side-Effects Of Quinolones & Fluoroquinolones

At the European Medicines Agency's second ever public hearing on the safety of marketed medicines, patients gave an emotional account of how they battled with 'ignorance' within the EU medical community about the severely debilitating and potentially permanent side-effects of some broad-spectrum antibiotics.

EMA Sets Date For Quinolone, Fluoroquinolone Public Hearing

People interested in participating in the European Medicines Agency’s second ever public hearing and sharing their experiences about the risks associated with quinolone and fluoroquinolone antibiotics must register to do so no later than April 30.

Related Content

Topics

UsernamePublicRestriction

Register

PS123260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel